News & Trends - Pharmaceuticals

Sanofi acquires Kymab biopharma to expand its immunotherapy pipeline

Health Industry Hub | January 13, 2021 |
[Total: 1    Average: 4/5]

Pharma News: Sanofi is set to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics.

The acquisition entails an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

The transaction will result in Sanofi having global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action.

“The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases. The novel mechanism of action may provide treatment for patients with suboptimal responses to available therapies,” said Paul Hudson, Sanofi Chief Executive Officer. 

Simon Sturge, Chief Executive Officer of Kymab, said “With its significant global resources, we believe Sanofi is the perfect partner to progress Kymab’s pipeline of products and the merger will expedite the time it takes for our novel therapies to get to patients.”

In August 2020, Kymab announced that KY1005 met both primary endpoints in a Phase 2a clinical trial studying moderate to severe atopic dermatitis patients whose disease is inadequately controlled with topical corticosteroids. KY1005 demonstrated a consistent treatment effect versus placebo across various key endpoints, including in the Eczema Area and Severity Index (EASI) and additional objective clinical measures.

“This acquisition aligns with our strategy of targeting fundamentally important disease pathways. We believe that OX40L, a key immune regulator, has the potential to rebalance the immune system without suppressing it, providing a promising new approach to treating a range of immune-mediated diseases,” said John Reed, M.D. Ph.D., Global Head of Research & Development at Sanofi.

Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination with an anti-PD-L1.

The deal is the latest acquisition for Sanofi. In November 2020, Sanofi spent $376 million on biotechnology company Kiadis, which specialises in cell-based immunotherapy products to treat cancer.

In August 2020, Sanofi acquired up autoimmune diseases specialist Principia Biopharma for $3.7 billion, following a $2.5 billion investment to acquire immuno-oncology treatments group Synthorx in December 2019.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Sustained COVID-19 impact on cancer services and procedures

Sustained COVID-19 impact on cancer services and procedures

Health Industry Hub | January 15, 2021 |

MedTech News: Cancer Australia has released the latest in a series of reports analysing for the first time the significance […]

More


News & Trends - Medical Technology

MedTech News - Healthscope hospital leading in high-tech medical surgery

Healthscope hospital leading in high-tech medical surgery

Health Industry Hub | January 15, 2021 |

MedTech News: Healthscope’s Knox Private Hospital recently celebrated two key milestones, underscoring its reputation as a leading proponent of high-tech […]

More


News & Trends - Pharmaceuticals

Pharma News - Experts comment on AstraZeneca vaccine efficacy concerns

Experts comment on AstraZeneca vaccine efficacy concerns

Health Industry Hub | January 15, 2021 |

Pharma News: In light of the comments made regarding AstraZeneca’s COVID-19 vaccine efficacy by the Australian and New Zealand Society […]

More


Communication

Communication Pharma Biotech Medtech - Secrets of persuasion to influence anyone

Secrets of persuasion to influence anyone

Health Industry Hub | January 15, 2021 |

To understand the art of persuasion, you can turn to cognitive science for guidance in dealing with the unconscious mind. […]

More